{"id":70806,"date":"2026-07-28T18:40:20","date_gmt":"2026-07-28T10:40:20","guid":{"rendered":"https:\/\/flcube.com\/?p=70806"},"modified":"2026-07-28T18:40:23","modified_gmt":"2026-07-28T10:40:23","slug":"cspcs-novel-snri-ammuxetine-meets-primary-endpoint-in-phase-iii-depression-trial-poised-for-first-line-status","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70806","title":{"rendered":"CSPC&#8217;s Novel SNRI Ammuxetine Meets Primary Endpoint in Phase III Depression Trial, Poised for First-Line Status"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CSPC Pharmaceutical Group Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1093:HKG\">HKG: 1093<\/a>) announced that the <strong>Phase III clinical trial<\/strong> of its <strong>self-developed Class 1 innovative drug<\/strong>, <strong>Ammuxetine Enteric-Coated Tablets (HA1406)<\/strong>, successfully met its <strong>primary efficacy endpoint<\/strong> in patients with <strong>major depressive disorder (MDD) \/ depression<\/strong>. The novel agent demonstrated <strong>statistically significant differences<\/strong> and <strong>clear clinical benefits<\/strong> with a <strong>favorable safety profile<\/strong>, positioning it as a promising candidate for <strong>first-line therapy<\/strong> in depression management.<\/p>\n\n\n\n<h2 id=\"h-trial-overview\" class=\"wp-block-heading\">Trial Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Sponsor<\/strong><\/td><td>CSPC Pharmaceutical Group Limited (HKG: 1093)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>Ammuxetine Enteric-Coated Tablets (HA1406)<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Class 1 innovative drug (China NMPA)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Novel, potent, and selective serotonin and norepinephrine reuptake inhibitor (SNRI)<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase III<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Major depressive disorder (MDD) \/ depression<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Met with statistical significance<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable<\/td><\/tr><tr><td><strong>Therapeutic Positioning<\/strong><\/td><td>Potential first-line therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Ammuxetine (HA1406)<\/li>\n\n\n\n<li><strong>Formulation:<\/strong> Enteric-coated tablets (optimized delivery)<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Dual inhibition of serotonin and norepinephrine reuptake<\/li>\n\n\n\n<li><strong>Pharmacological Advantage:<\/strong> Enhanced selectivity profile compared to existing SNRIs<\/li>\n\n\n\n<li><strong>Innovation Status:<\/strong> Self-developed Class 1 innovative drug representing significant domestic pharmaceutical advancement<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-highlights\" class=\"wp-block-heading\">Clinical Evidence Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Result<\/th><th>Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Efficacy Endpoint<\/strong><\/td><td>Met<\/td><td>Statistically significant difference vs. control<\/td><\/tr><tr><td><strong>Clinical Benefit<\/strong><\/td><td>Clear and meaningful<\/td><td>Meets regulatory and clinical practice thresholds<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable<\/td><td>Supports chronic dosing in depression management<\/td><\/tr><tr><td><strong>Therapeutic Index<\/strong><\/td><td>Optimized<\/td><td>Balances efficacy with tolerability for first-line use<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The trial results demonstrate that Ammuxetine achieves the critical balance required for first-line antidepressant therapy: robust efficacy combined with manageable side effects suitable for long-term treatment.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-implications\" class=\"wp-block-heading\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Depression Treatment Landscape:<\/strong> Addresses significant unmet need in China&#8217;s estimated <strong>95 million adults<\/strong> affected by depression, with only <strong>8% receiving adequate treatment<\/strong><\/li>\n\n\n\n<li><strong>First-Line Opportunity:<\/strong> Potential to compete with established global SNRIs including <strong>venlafaxine, duloxetine, and desvenlafaxine<\/strong>, which collectively generate <strong>$3+ billion annually<\/strong> in major markets<\/li>\n\n\n\n<li><strong>China Innovation Leadership:<\/strong> As a Class 1 innovative drug, Ammuxetine represents CSPC&#8217;s commitment to developing truly novel therapeutics rather than me-too compounds<\/li>\n\n\n\n<li><strong>Commercial Advantages:<\/strong><\/li>\n\n\n\n<li>Domestic manufacturing ensures supply chain security<\/li>\n\n\n\n<li>Potential pricing advantages over imported alternatives<\/li>\n\n\n\n<li>Alignment with China&#8217;s healthcare cost-containment policies<\/li>\n\n\n\n<li><strong>Global Expansion Potential:<\/strong> Successful development could support international regulatory filings, particularly in emerging markets seeking affordable, effective depression treatments<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for Ammuxetine. Actual results may differ due to risks including regulatory decisions, competitive dynamics, market acceptance, and additional data requirements for marketing approval.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072701166_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026072701166_c.\"><\/object><a id=\"wp-block-file--media-64057d13-6832-43de-ad98-2376e1650ddf\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072701166_c.pdf\">2026072701166_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072701166_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-64057d13-6832-43de-ad98-2376e1650ddf\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the Phase III clinical trial of its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[17,171,855],"class_list":["post-70806","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-cspc-pharmaceutical","tag-hkg-1093"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC&#039;s Novel SNRI Ammuxetine Meets Primary Endpoint in Phase III Depression Trial, Poised for First-Line Status - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the Phase III clinical trial of its self-developed Class 1 innovative drug, Ammuxetine Enteric-Coated Tablets (HA1406), successfully met its primary efficacy endpoint in patients with major depressive disorder (MDD) \/ depression. The novel agent demonstrated statistically significant differences and clear clinical benefits with a favorable safety profile, positioning it as a promising candidate for first-line therapy in depression management.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70806\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC&#039;s Novel SNRI Ammuxetine Meets Primary Endpoint in Phase III Depression Trial, Poised for First-Line Status\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the Phase III clinical trial of its self-developed Class 1 innovative drug, Ammuxetine Enteric-Coated Tablets (HA1406), successfully met its primary efficacy endpoint in patients with major depressive disorder (MDD) \/ depression. The novel agent demonstrated statistically significant differences and clear clinical benefits with a favorable safety profile, positioning it as a promising candidate for first-line therapy in depression management.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70806\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-28T10:40:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-28T10:40:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70806#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70806\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC&#8217;s Novel SNRI Ammuxetine Meets Primary Endpoint in Phase III Depression Trial, Poised for First-Line Status\",\"datePublished\":\"2026-07-28T10:40:20+00:00\",\"dateModified\":\"2026-07-28T10:40:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70806\"},\"wordCount\":407,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"CSPC Pharmaceutical\",\"HKG: 1093\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70806#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70806\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70806\",\"name\":\"CSPC's Novel SNRI Ammuxetine Meets Primary Endpoint in Phase III Depression Trial, Poised for First-Line Status - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-28T10:40:20+00:00\",\"dateModified\":\"2026-07-28T10:40:23+00:00\",\"description\":\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the Phase III clinical trial of its self-developed Class 1 innovative drug, Ammuxetine Enteric-Coated Tablets (HA1406), successfully met its primary efficacy endpoint in patients with major depressive disorder (MDD) \\\/ depression. The novel agent demonstrated statistically significant differences and clear clinical benefits with a favorable safety profile, positioning it as a promising candidate for first-line therapy in depression management.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70806#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70806\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70806#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC&#8217;s Novel SNRI Ammuxetine Meets Primary Endpoint in Phase III Depression Trial, Poised for First-Line Status\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC's Novel SNRI Ammuxetine Meets Primary Endpoint in Phase III Depression Trial, Poised for First-Line Status - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the Phase III clinical trial of its self-developed Class 1 innovative drug, Ammuxetine Enteric-Coated Tablets (HA1406), successfully met its primary efficacy endpoint in patients with major depressive disorder (MDD) \/ depression. The novel agent demonstrated statistically significant differences and clear clinical benefits with a favorable safety profile, positioning it as a promising candidate for first-line therapy in depression management.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70806","og_locale":"en_US","og_type":"article","og_title":"CSPC's Novel SNRI Ammuxetine Meets Primary Endpoint in Phase III Depression Trial, Poised for First-Line Status","og_description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the Phase III clinical trial of its self-developed Class 1 innovative drug, Ammuxetine Enteric-Coated Tablets (HA1406), successfully met its primary efficacy endpoint in patients with major depressive disorder (MDD) \/ depression. The novel agent demonstrated statistically significant differences and clear clinical benefits with a favorable safety profile, positioning it as a promising candidate for first-line therapy in depression management.","og_url":"https:\/\/flcube.com\/?p=70806","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-28T10:40:20+00:00","article_modified_time":"2026-07-28T10:40:23+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70806#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70806"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC&#8217;s Novel SNRI Ammuxetine Meets Primary Endpoint in Phase III Depression Trial, Poised for First-Line Status","datePublished":"2026-07-28T10:40:20+00:00","dateModified":"2026-07-28T10:40:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70806"},"wordCount":407,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","CSPC Pharmaceutical","HKG: 1093"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70806#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70806","url":"https:\/\/flcube.com\/?p=70806","name":"CSPC's Novel SNRI Ammuxetine Meets Primary Endpoint in Phase III Depression Trial, Poised for First-Line Status - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-28T10:40:20+00:00","dateModified":"2026-07-28T10:40:23+00:00","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the Phase III clinical trial of its self-developed Class 1 innovative drug, Ammuxetine Enteric-Coated Tablets (HA1406), successfully met its primary efficacy endpoint in patients with major depressive disorder (MDD) \/ depression. The novel agent demonstrated statistically significant differences and clear clinical benefits with a favorable safety profile, positioning it as a promising candidate for first-line therapy in depression management.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70806#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70806"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70806#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC&#8217;s Novel SNRI Ammuxetine Meets Primary Endpoint in Phase III Depression Trial, Poised for First-Line Status"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70806"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70806\/revisions"}],"predecessor-version":[{"id":70808,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70806\/revisions\/70808"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}